Clinical Trials Logo

Filter by:
NCT ID: NCT05600387 Enrolling by invitation - Heart Failure Clinical Trials

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Start date: November 5, 2022
Phase: Phase 4
Study type: Interventional

The number of heart failure with mildly reduced or preserved ejection fraction gradually increases. SGLT2-i has been shown to reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or more . However,its effect on the function on left atrium in heart failure with mildly reduced or preserved ejection fraction is still unknown.

NCT ID: NCT05600335 Completed - Clinical trials for Esophageal Cancer Patients

Short-term Outcomes of ERAS Protocol in RAME for Esophageal Cancer

Start date: January 1, 2019
Phase:
Study type: Observational

This single-center, retrospective cohort study aimed to evaluate the short-term outcomes of enhanced recovery after surgery (ERAS) protocol in perioperative robotic-assisted McKeown esophagectomy (RAME) among esophageal cancer patients.

NCT ID: NCT05600322 Completed - Bladder Cancer Clinical Trials

Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

Start date: November 3, 2022
Phase: Phase 3
Study type: Interventional

A study to compare Hexvix Blue light cstoscopy with standard White light cystoscopy in the detection of bladder cancer.

NCT ID: NCT05600309 Active, not recruiting - Colorectal Cancer Clinical Trials

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Start date: June 14, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this China extension study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in adult Chinese participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil). The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.

NCT ID: NCT05600153 Not yet recruiting - Clinical trials for Breast Reconstruction

Axillary Versus Primary Breast Approach for Second-stage Breast Reconstruction

AvBSR
Start date: December 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the safety of axillary or primary breast approach for second-stage operation in expander-implant breast reconstruction for breast cancer patients. The main question it aims to answer are: 1. if the wound related events, including wound dehiscence, infection, delayed healing is significant less often in patients receiving second stage operation via axillary approach compared with primary breast approach; 2. if the aesthetic outcome is comparable between patients receiving different approach for second stage operation. To answer these questions, the breast cancer patients have received nipple-sparing or skin-sparing mastectomy and had breast tissue expander insertion via breast incision, will be prospectively recruited, and randomized into two groups while receiving implant exchange operation: (1) operate via axillary incision; (2) operate via primary breast incision.

NCT ID: NCT05599789 Recruiting - Clinical trials for Non Small Cell Lung Cancer Metastatic

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

KeyPemls-004
Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.

NCT ID: NCT05599373 Recruiting - Schizophrenia Clinical Trials

Optimal rTMS for Cognitive Deficits and Negative Symptoms in Schizophrenia

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Negative symptoms and cognition decline are major challenges in clinical management of schizophrenia. Dorsomedial prefrontal cortex (DLPFC) has been highly involved in the mechanisms of negative symptoms and cognitive symptoms of schizophrenia. However, the effect of repetitive transcranial magnetic stimulation (rTMS) over left or bilateral DLPFC has not yet been well studied. The aim of this study is to describe how the effectiveness of rTMS over different targets for cognitive deficits and negative symptoms in schizophrenia will be evaluated. The study will provide evidence to determine whether a bilateral DLPFC rTMS and is more effective than a left DLPFC rTMS alone to optimize treatment protocol in schizophrenia.

NCT ID: NCT05599256 Recruiting - Clinical trials for Transplant-Related Disorder

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Start date: February 9, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of child patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model.

NCT ID: NCT05599217 Recruiting - Clinical trials for Chronic Subdural Hematoma

Association Between Dietary Factors and Chronic Subdural Hematoma (DISH)

DISH
Start date: March 13, 2023
Phase:
Study type: Observational

A prospective, multicenter, case control trial is designed to compare difference in dietary and nutritional factors in patients with and without chronic subdural hematoma.

NCT ID: NCT05599126 Not yet recruiting - Depression Clinical Trials

A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems

Start date: December 2022
Phase: Phase 4
Study type: Interventional

Patients with depression with sleep problems have functional abnormalities of 5-HT and NE neurotransmitters, and the NaSSA class antidepressant mianserin has an ameliorative effect on sleep problems along with antidepressant. However, whether mianserin can improve cognitive function in patients still needs to be explored. The benzodiazepine lorazepam can play a central inhibitory role and has good therapeutic effect on insomnia. The mechanism of action of mianserin and lorazepam is different, and there are few comparative studies related to the combination of the two with SSRI drugs for the treatment of depressed patients with sleep problems, and it is unclear whether there are differences in their efficacy and safety. Therefore, to address the above scientific questions, this study was designed to include 100 patients aged 18-60 years with depression with sleep problems, randomly divided into two groups and treated with mianserin + escitalopram or lorazepam + escitalopram, respectively, and followed up for 8 weeks to assess depression and anxiety symptoms, sleep, cognitive function and drug safety. To compare the efficacy and safety of the two regimens in depressed patients with sleep problems and to provide a scientific basis for clinical intervention in depressed patients with sleep problems.